JP6692816B2 - 炎症を処置および予防するための組成物および方法 - Google Patents

炎症を処置および予防するための組成物および方法 Download PDF

Info

Publication number
JP6692816B2
JP6692816B2 JP2017531928A JP2017531928A JP6692816B2 JP 6692816 B2 JP6692816 B2 JP 6692816B2 JP 2017531928 A JP2017531928 A JP 2017531928A JP 2017531928 A JP2017531928 A JP 2017531928A JP 6692816 B2 JP6692816 B2 JP 6692816B2
Authority
JP
Japan
Prior art keywords
nrp1
trap
seq
sema3a
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017531928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527616A5 (enExample
JP2017527616A (ja
Inventor
サピエハ プシェミスワフ
サピエハ プシェミスワフ
ボーリュー ノルマン
ボーリュー ノルマン
Original Assignee
アールエスイーエム，リミティド パートナーシップ
アールエスイーエム，リミティド パートナーシップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アールエスイーエム，リミティド パートナーシップ, アールエスイーエム，リミティド パートナーシップ filed Critical アールエスイーエム，リミティド パートナーシップ
Publication of JP2017527616A publication Critical patent/JP2017527616A/ja
Publication of JP2017527616A5 publication Critical patent/JP2017527616A5/ja
Application granted granted Critical
Publication of JP6692816B2 publication Critical patent/JP6692816B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
JP2017531928A 2014-09-05 2015-09-08 炎症を処置および予防するための組成物および方法 Active JP6692816B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046459P 2014-09-05 2014-09-05
US62/046,459 2014-09-05
PCT/CA2015/050862 WO2016033699A1 (en) 2014-09-05 2015-09-08 Compositions and methods for treating and preventing inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020070982A Division JP7194146B2 (ja) 2014-09-05 2020-04-10 炎症を処置および予防するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2017527616A JP2017527616A (ja) 2017-09-21
JP2017527616A5 JP2017527616A5 (enExample) 2018-10-18
JP6692816B2 true JP6692816B2 (ja) 2020-05-13

Family

ID=55438956

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017531928A Active JP6692816B2 (ja) 2014-09-05 2015-09-08 炎症を処置および予防するための組成物および方法
JP2020070982A Active JP7194146B2 (ja) 2014-09-05 2020-04-10 炎症を処置および予防するための組成物および方法
JP2022196745A Pending JP2023022308A (ja) 2014-09-05 2022-12-09 炎症を処置および予防するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020070982A Active JP7194146B2 (ja) 2014-09-05 2020-04-10 炎症を処置および予防するための組成物および方法
JP2022196745A Pending JP2023022308A (ja) 2014-09-05 2022-12-09 炎症を処置および予防するための組成物および方法

Country Status (17)

Country Link
US (4) US10738122B2 (enExample)
EP (1) EP3189074B1 (enExample)
JP (3) JP6692816B2 (enExample)
KR (2) KR102696275B1 (enExample)
CN (2) CN113980116A (enExample)
AU (1) AU2015311563B2 (enExample)
CA (1) CA2960054C (enExample)
DK (1) DK3189074T3 (enExample)
ES (1) ES2865488T3 (enExample)
HR (1) HRP20210577T1 (enExample)
HU (1) HUE054204T2 (enExample)
LT (1) LT3189074T (enExample)
PL (1) PL3189074T3 (enExample)
PT (1) PT3189074T (enExample)
RS (1) RS61703B1 (enExample)
SI (1) SI3189074T1 (enExample)
WO (1) WO2016033699A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437462B2 (ja) 2013-02-21 2018-12-12 アールエスイーエム・リミテッド・パートナーシップ 眼内透過性亢進の予防及び治療におけるｓｅｍａ３ａの阻害
WO2016033699A1 (en) 2014-09-05 2016-03-10 Rsem, Limited Partnership Compositions and methods for treating and preventing inflammation
DK3353196T5 (da) * 2015-09-22 2024-09-30 Inst Nat Sante Rech Med Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
US20200056186A1 (en) * 2016-09-22 2020-02-20 Rsem, Limited Partnership Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence
US20190330640A1 (en) * 2017-01-09 2019-10-31 Secarna Pharmaceuticals Gmbh & Co. Kg Oligonucleotides inhibiting the expression of nrp1
CN110290785A (zh) * 2017-03-08 2019-09-27 日清奥利友集团株式会社 抗炎症剂、抗炎症用药物组合物、抗炎症用食品组合物
JOP20210300A1 (ar) * 2019-05-09 2023-01-30 Boehringer Ingelheim Int أجسام مضادة مضادة لسيما 3أ واستخداماتها في علاج أمراض العين أو البصر
TWI865542B (zh) 2019-06-12 2024-12-11 瑞士商諾華公司 利鈉肽受體1抗體及使用方法
TWI859339B (zh) * 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
CN112641928A (zh) * 2019-10-11 2021-04-13 田中纯美 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途
EP4157312A4 (en) * 2020-05-27 2024-07-31 Baylor College of Medicine COMPOSITIONS AND METHODS FOR TREATING NEOVASCULARIZATION AND ISCHEMIC RETINOPATHIES BY TARGETING ANGIOGENESIS AND CHOLESTEROL TRANSPORT
WO2021258218A1 (en) * 2020-06-26 2021-12-30 Semathera Inc. Use of soluble nrp1 polypeptides for the treatment of coronavirus infections
US20230312684A1 (en) * 2020-07-31 2023-10-05 Pinetree Therapeutics, Inc. Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections
CN118201628A (zh) 2021-09-08 2024-06-14 斯特拉斯堡大学 丛蛋白a1的跨膜肽拮抗剂及其治疗应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4806463A (en) 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en) 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5098890A (en) 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
AUPM516994A0 (en) 1994-04-20 1994-05-12 Gene Shears Pty. Limited An in vivo gene expression system
US20020132788A1 (en) 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
EP1418834A4 (en) 2001-07-20 2007-04-04 Sinai School Medicine METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE AND PARKINSON DISEASE
EP1429801A1 (en) 2001-09-26 2004-06-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neuropilin as a novel therapeutic target for modulation of immune reponses
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
AU2006267097A1 (en) 2005-07-13 2007-01-18 Beth Israel Deaconess Medical Center Methods of diagnosing and treating an inflammatory response
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
MX2009012282A (es) 2007-05-17 2009-11-25 Genentech Inc Estructuras cristalinas de fragmentos de neuropilina y complejos de neuropilina-anticuerpos.
CN103193888B (zh) * 2007-05-17 2015-09-09 健泰科生物技术公司 神经毡蛋白片段与神经毡蛋白抗体复合物的晶体结构
WO2009060159A1 (en) 2007-11-08 2009-05-14 Medigene Limited Mutated ilt molecules
EP3275898B1 (en) * 2009-11-05 2024-06-05 Osaka University Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
EP2613773A2 (en) * 2010-09-09 2013-07-17 Trifoilium ApS Airway administration of angiogenesis inhibitors
ES2728854T3 (es) 2013-02-06 2019-10-29 Univ Yokohama City Anticuerpo anti-semaforina 3A y tratamiento de enfermedad de Alzheimer y enfermedades inmunitarias inflamatorias usando el mismo
JP6437462B2 (ja) 2013-02-21 2018-12-12 アールエスイーエム・リミテッド・パートナーシップ 眼内透過性亢進の予防及び治療におけるｓｅｍａ３ａの阻害
WO2016033699A1 (en) 2014-09-05 2016-03-10 Rsem, Limited Partnership Compositions and methods for treating and preventing inflammation

Also Published As

Publication number Publication date
RS61703B1 (sr) 2021-05-31
LT3189074T (lt) 2021-06-10
JP2020147568A (ja) 2020-09-17
HRP20210577T1 (hr) 2021-05-28
HUE054204T2 (hu) 2021-08-30
EP3189074A4 (en) 2018-06-20
US10738122B2 (en) 2020-08-11
EP3189074A1 (en) 2017-07-12
US11649292B2 (en) 2023-05-16
SI3189074T1 (sl) 2021-08-31
CA2960054A1 (en) 2016-03-10
JP2017527616A (ja) 2017-09-21
KR102869487B1 (ko) 2025-10-14
PL3189074T3 (pl) 2021-08-02
US20170283502A1 (en) 2017-10-05
AU2015311563A1 (en) 2017-03-16
CN107207577B (zh) 2021-11-09
DK3189074T3 (da) 2021-04-19
US10766964B2 (en) 2020-09-08
WO2016033699A1 (en) 2016-03-10
US20230265199A1 (en) 2023-08-24
ES2865488T3 (es) 2021-10-15
AU2015311563B2 (en) 2019-11-28
JP7194146B2 (ja) 2022-12-21
PT3189074T (pt) 2021-04-19
EP3189074B1 (en) 2021-01-13
KR102696275B1 (ko) 2024-08-21
US20210061915A1 (en) 2021-03-04
CN107207577A (zh) 2017-09-26
JP2023022308A (ja) 2023-02-14
CN113980116A (zh) 2022-01-28
KR20240125991A (ko) 2024-08-20
KR20170044691A (ko) 2017-04-25
US20190359718A1 (en) 2019-11-28
CA2960054C (en) 2023-11-14

Similar Documents

Publication Publication Date Title
JP7194146B2 (ja) 炎症を処置および予防するための組成物および方法
JP2017527616A5 (enExample)
Dejda et al. Neuropilin-1 mediates myeloid cell chemoattraction and influences retinal neuroimmune crosstalk
CN110023332B (zh) 包含sasp调节剂和衰老衰减剂的组合物及其用于调节细胞衰老的用途
JP6437462B2 (ja) 眼内透過性亢進の予防及び治療におけるｓｅｍａ３ａの阻害
JP6689484B2 (ja) 網膜炎症の治療において使用するための薬剤
HK1238571A1 (en) Compositions and methods for treating and preventing inflammation
HK1238571B (en) Compositions and methods for treating and preventing inflammation
Kakogiannos Molecular insights of Gpr126 signalling in the angiogenesis and pathology of ischaemic stroke

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200326

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200415

R150 Certificate of patent or registration of utility model

Ref document number: 6692816

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250